Get the Stockscreener App
14.77
0.74%
-0.11
Pre-market:
14.77
Ultragenyx Pharmaceutical Inc stock is traded at $14.77, with a volume of 3.48M.
It is down -0.74% in the last 24 hours and down -42.57% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
See More
Previous Close:
$14.88
Open:
$14.73
24h Volume:
3.48M
Relative Volume:
0.93
Market Cap:
$1.46B
Revenue:
$669.43M
Net Income/Loss:
$-609.36M
P/E Ratio:
-2.4189
EPS:
-6.1061
Net Cash Flow:
$-507.20M
1W Performance:
+1.86%
1M Performance:
-42.57%
6M Performance:
-20.16%
1Y Performance:
-48.64%
1-Day Range:
$14.54
$14.87
1-Week Range:
$14.07
$16.12
52-Week Range:
$12.73
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
14.77 | 1.46B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | Goldman | Buy → Neutral |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
Why Did RARE Stock Slump 46% After-Hours? - Stocktwits
A Hedge Fund Rolls the Dice on Ultragenyx - Law Street Media
Ultragenyx Stock Jumps on Landmark FDA Approval - Barron's
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz - BioSpace
Treatment invented at Nationwide Children’s for deadly disease gets FDA approval - The Business Journals
Understanding the Setup: (RARE) and Scalable Risk - Stock Traders Daily
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results - finance.yahoo.com
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target? - finance.yahoo.com
Bank of America Corp DE Invests $38.35 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
RARE Maintained by Evercore ISI Group -- Price Target Raised to $18 - GuruFocus
Is Ultragenyx Stock a Buy With 2 FDA Vouchers Worth a Quarter of Its Market Value? - Investing.com
RARE Maintained by Barclays -- Price Target Raised to $35.00 - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Andelyn Biosciences reaches commercial gene therapy manufacturing milestone with Fayuvi - Manufacturing Chemist
Why Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is In Focus Now? - Kalkine Media
Ultragenyx wins first-ever FDA approval in Sanfilippo syndrome type A - The Pharma Letter
Ultragenyx Pharmaceutical stock gains after FDA approval and fresh analyst targets - AD HOC NEWS
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI - finance.yahoo.com
Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending - webull.com
FDA approves new gene therapy as first treatment for Sanfilippo A - Sanfilippo Syndrome News
Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo - MedCity News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out - accessnewswire.com
RARE - Finviz
Ultragenyx's $3.95 Million Fayuvi Secures First-Ever FDA Approval for Sanfilippo Syndrome Type A - finance.biggo.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A - BioPharm International
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy - theglobeandmail.com
Ultragenyx Turns To Launch Execution After Long Road For Sanfilippo Gene Therapy - insights.citeline.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00 - MarketBeat
Ultragenyx sets $3.95 million price for rare disease gene therapy - cnbc.com
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A - Pharmaceutical Executive
Ultragenyx secures FDA approval for first treatment of Sanfilippo syndrome type A - AllSci
Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest - Benzinga
Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVI™ to Treat Sanfilippo Syndrome Type A (MPS IIIA) - PR Newswire
Ultragenyx Pharmaceutical stock jumps on Fayuvi FDA approval and fresh Cantor Fitzgerald target - AD HOC NEWS
Canaccord Genuity Group Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $39.00 - MarketBeat
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M - BioSpace
FDA approves Ultragenyx gene therapy for rare disorder MPS IIIA - Investing.com
Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Cantor Fitzgerald raises Ultragenyx stock price target on gene therapy approval - Investing.com
Abeona Therapeutics (ABEO) Congratulates Ultragenyx on FDA Appro - GuruFocus
FDA approves Ultragenyx gene therapy for rare disorder MPS IIIA By Investing.com - Investing.com Nigeria
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) - manilatimes.net
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):